1
|
Ruiz C, Alborelli I, Manzo M, Calgua B, Keller E, Vuaroqueaux V, Quagliata L, Rentsch CA, Spagnoli GC, Diener PA, Bubendorf L, Morant R, Eppenberger-Castori S. Critical Evaluation of Transcripts and Long Noncoding RNA Expression Levels in Prostate Cancer Following Radical Prostatectomy. Pathobiology 2023; 90:400-408. [PMID: 37463569 PMCID: PMC10733933 DOI: 10.1159/000531175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 05/18/2023] [Indexed: 07/20/2023] Open
Abstract
INTRODUCTION The clinical course of prostate cancer (PCa) is highly variable, ranging from indolent behavior to rapid metastatic progression. The Gleason score is widely accepted as the primary histologic assessment tool with significant prognostic value. However, additional biomarkers are required to better stratify patients, particularly those at intermediate risk. METHODS In this study, we analyzed the expression of 86 cancer hallmark genes in 171 patients with PCa who underwent radical prostatectomy and focused on the outcome of the 137 patients with postoperative R0-PSA0 status. RESULTS Low expression of the IGF1 and SRD52A, and high expression of TIMP2, PLAUR, S100A2, and CANX genes were associated with biochemical recurrence (BR), defined as an increase of prostate-specific antigen above 0.2 ng/mL. Furthermore, the analysis of the expression of 462 noncoding RNAs (ncRNA) in a sub-cohort of 39 patients with Gleason score 7 tumors revealed that high levels of expression of the ncRNAs LINC00624, LINC00593, LINC00482, and cd27-AS1 were significantly associated with BR. Our findings provide further evidence for tumor-promoting roles of ncRNAs in PCa patients at intermediate risk. The strong correlation between expression of LINC00624 and KRT8 gene, encoding a well-known cell surface protein present in PCa, further supports a potential contribution of this ncRNA to PCa progression. CONCLUSION While larger and further studies are needed to define the role of these genes/ncRNA in PCa, our findings pave the way toward the identification of a subgroup of patients at intermediate risk who may benefit from adjuvant treatments and new therapeutic agents.
Collapse
Affiliation(s)
- Christian Ruiz
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Ilaria Alborelli
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Massimiliano Manzo
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Byron Calgua
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Eveline Keller
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | | | - Luca Quagliata
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
- Medical Affairs Team, Genetic Sciences Group, Thermo Fisher Scientific, Monza, Italy
| | - Cyrill A. Rentsch
- Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Giulio C. Spagnoli
- National Research Council, Institute of Translational Pharmacology, Rome, Italy
| | | | - Lukas Bubendorf
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Rudolf Morant
- Tumor-und Brustzentrum ZeTuP, St. Gallen, Switzerland
| | - on behalf of the former members of the Urology Team in St. Gallen**
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
- 4HF Biotec, Freiburg, Germany
- Medical Affairs Team, Genetic Sciences Group, Thermo Fisher Scientific, Monza, Italy
- Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland
- National Research Council, Institute of Translational Pharmacology, Rome, Italy
- Pathology, Kantonsspital St. Gallen, St. Gallen, Switzerland
- Tumor-und Brustzentrum ZeTuP, St. Gallen, Switzerland
| | | |
Collapse
|
2
|
Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC Cancer 2021; 21:229. [PMID: 33676446 PMCID: PMC7936440 DOI: 10.1186/s12885-021-07917-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 02/15/2021] [Indexed: 12/29/2022] Open
Abstract
Background A recent study found an influence of organized mammography screening programmes (MSPs) on geographical and temporal variation of mastectomy rates. We aimed to quantify the effect on the example of one of the cantonal programmes in Switzerland. Methods We used incidence data for the years 2010–2017 from the cancer registry of Eastern Switzerland. We included women with invasive-non-metastatic breast cancer (BC) in the screening age group 50–69-year-olds in the canton of St.Gallen. We compared mastectomy rates among cancer patients detected through the organised screening programme (MSP) vs. otherwise detected by stage. Results MSP-detected patients in St.Gallen presented with lower stages. 95% of MSP-detected had stages I-II vs 76% of Non-MSP-detected. Within all non-metastatic stage, tumour size and nodal status groups, MSP-detected patients had lower mastectomy rates, overall 10% vs 24% in 50–69-year-old non-participants. Their odds of receiving a mastectomy are about half of the Non-MSP-detected (OR = 0.48, p = 0.002). Conclusions Our study showed that MSPs have a positive effect on lowering mastectomy rates. Screening participants are significantly less likely to receive a mastectomy compared to non-participants, which must be attributed to additional factors than just lower stages. Lower mastectomy rates lead to a higher quality of life for many patients.
Collapse
Affiliation(s)
- Christian Herrmann
- Cancer Registry of Eastern Switzerland, Cancer League of Eastern Switzerland, St. Gallen, Switzerland.
| | - Rudolf Morant
- Cancer League of Eastern Switzerland, St. Gallen, Switzerland
| | - Esther Walser
- Cancer Registry of Eastern Switzerland, Cancer League of Eastern Switzerland, St. Gallen, Switzerland
| | - Mohsen Mousavi
- Cancer Registry of Eastern Switzerland, Cancer League of Eastern Switzerland, St. Gallen, Switzerland
| | - Beat Thürlimann
- Division Oncology-Haematology, Department of Internal Medicine, St. Gallen, Switzerland.,Breast Centre St.Gallen, Cantonal Hospital, St. Gallen, Switzerland
| |
Collapse
|
3
|
Affiliation(s)
- Friedrich Stiefel
- Palliativstation, Division of Hematology/Oncology, Kantonsspital, St. Gallen, Switzerland
| | - Rudolf Morant
- Palliativstation, Division of Hematology/Oncology, Kantonsspital, St. Gallen, Switzerland
| |
Collapse
|
4
|
Affiliation(s)
- Rudolf Morant
- Palliative Care Unit, Medizin C, Kantonsspital, St. Gallen, Switzerland
| |
Collapse
|
5
|
Herrmann C, Ess S, Walser E, Frick H, Thürlimann B, Probst-Hensch N, Rothermundt C, Mousavi M, Morant R, Vounatsou P. Screening is associated with lower mastectomy rates in Switzerland. Breast 2019. [DOI: 10.1016/s0960-9776(19)30196-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Stenner F, Rothschild SI, Betticher D, Caspar C, Morant R, Popescu R, Rauch D, Huber U, Zenhäusern R, Rentsch C, Cathomas R. Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. Clin Genitourin Cancer 2017; 16:S1558-7673(17)30244-6. [PMID: 28958629 DOI: 10.1016/j.clgc.2017.08.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 08/07/2017] [Accepted: 08/12/2017] [Indexed: 12/22/2022]
Abstract
BACKGROUND The aim was to evaluate quality of life (QoL), pain, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with different regimens after first-line docetaxel, as well as disease progression. PATIENTS AND METHODS Patients with mCRPC having received first-line chemotherapy with docetaxel were eligible. Second-line treatment choice was at the discretion of the local investigator. All patients had regular assessments of QoL with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, of fatigue with the Brief Fatigue Inventory, and of pain with the McGill Pain Questionnaire-Short Form. The primary end point was QoL maintenance defined as having a maximum decrease in 2 functional domains of the FACT-P. RESULTS One hundred thirty-eight patients were included in 36 oncology centers across Switzerland. QoL analysis was available for all patients (59 who received cabazitaxel; 79 who received other therapy [OT] including 75 who received abiraterone). No significant differences for any of the end points were found between groups. A numerically higher number of patients had QoL maintenance with OT (25 of 79 patients, 32%) compared with cabazitaxel (8 of 59 patients, 14%). QoL improvement was found in 20% of patients (12 of 59) who received cabazitaxel and 24% (19 of 79) who received OT. Mean FACT-P score did not change in a clinically relevant manner over time in either group. Pain was present in 70% of patients (96 of 138), and a pain response to treatment was noted in 22% (13 of 59) who received cabazitaxel and 29% (23 of 79) who received OT. A similar but minor improvement of fatigue was noted in both groups. CONCLUSION Some degree of QoL decrease was seen in most patients regardless of second-line treatment. No significant differences in QoL parameters between cabazitaxel or other second line treatments were found.
Collapse
Affiliation(s)
- Frank Stenner
- Department of Oncology, University Hospital Basel, Basel, Switzerland
| | | | - Daniel Betticher
- Department of Oncology, Cantonal Hospital, Fribourg, Switzerland
| | - Clemens Caspar
- Department of Oncology, Cantonal Hospital, Baden, Switzerland
| | - Rudolf Morant
- Center for Tumors and Prevention ZeTuP, Rapperswil-Jona, Switzerland
| | - Razvan Popescu
- Division of Oncology, Hirslanden Medical Center, Aarau, Switzerland
| | - Daniel Rauch
- Division of Oncology, Hospital Thun, Thun, Switzerland
| | - Urs Huber
- Oncology Center, Hirslanden Clinic, Zürich, Switzerland
| | | | - Cyrill Rentsch
- Department of Oncology, University Hospital Basel, Basel, Switzerland
| | - Richard Cathomas
- Department of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland.
| |
Collapse
|
7
|
Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox KA, Lam WL, Gleave M, Chi KN, Pandha H, Wang Y, Helgason CD. Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Mol Oncol 2016; 10:693-703. [PMID: 26809501 PMCID: PMC5423162 DOI: 10.1016/j.molonc.2015.12.010] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Revised: 11/13/2015] [Accepted: 12/07/2015] [Indexed: 12/12/2022] Open
Abstract
Metastasis is the primary cause of death in prostate cancer (PCa) patients. Small nucleolar RNAs (snoRNAs) have long been considered "housekeeping" genes with no relevance for cancer biology. Emerging evidence has challenged this assumption, suggesting that snoRNA expression is frequently modulated during cancer progression. Despite this, no study has systematically addressed the prognostic and functional significance of snoRNAs in PCa. We performed RNA Sequencing on paired metastatic/non-metastatic PCa xenografts derived from clinical specimens. The clinical significance of differentially expressed snoRNAs was further investigated in two independent primary PCa cohorts (131 and 43 patients, respectively). The snoRNA demonstrating the strongest association with clinical outcome was quantified in PCa patient-derived serum samples and its functional relevance was investigated in PCa cells via gene expression profiling, pathway analysis and gene silencing. Our comparison revealed 21 differentially expressed snoRNAs in the metastatic vs. non-metastatic xenografts. Of those, 12 were represented in clinical databases and were further analyzed. SNORA55 emerged as a predictor of shorter relapse-free survival (results confirmed in two independent databases). SNORA55 was reproducibly detectable in serum samples from PCa patients. SNORA55 silencing in PCa cell lines significantly inhibited cell proliferation and migration. Pathway analysis revealed that SNORA55 expression is significantly associated with growth factor signaling and pro-inflammatory cytokine expression in PCa. Our results demonstrate that SNORA55 up-regulation predicts PCa progression and that silencing this non-coding gene affects PCa cell proliferation and metastatic potential, thus positioning it as both a novel biomarker and therapeutic target.
Collapse
Affiliation(s)
- Francesco Crea
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada; The Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver BC, Canada; Department of Life, Health, and Chemical Sciences, The Open University, Milton Keynes, UK
| | - Luca Quagliata
- Molecular Pathology Unit, Institute of Pathology University Hospital Basel, Switzerland
| | - Agnieszka Michael
- Oncology, FHMS, School of Biosciences and Medicine, University of Surrey, UK
| | - Hui Hsuan Liu
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada
| | - Paolo Frumento
- Karolinska Institutet, Institute of Environmental Medicine, Unit of Biostatistics, Stockholm, Sweden
| | - Arun A Azad
- Medical Oncology, BC Cancer Agency Vancouver Cancer Centre, Vancouver BC, Canada
| | - Hui Xue
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada
| | - Larissa Pikor
- Genetics Unit, Integrative Oncology, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada
| | - Akira Watahiki
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada; The Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver BC, Canada
| | - Rudolf Morant
- Cancer Center ZeTuP AG St.Gallen, St.Gallen, Switzerland
| | | | - Yuwei Wang
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada
| | - Abhijit Parolia
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada
| | - Kim A Lennox
- Integrated DNA Technologies, Coralville, IA, USA
| | - Wan L Lam
- Genetics Unit, Integrative Oncology, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada
| | - Martin Gleave
- The Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver BC, Canada
| | - Kim N Chi
- The Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver BC, Canada; Medical Oncology, BC Cancer Agency Vancouver Cancer Centre, Vancouver BC, Canada
| | - Hardev Pandha
- Oncology, FHMS, School of Biosciences and Medicine, University of Surrey, UK
| | - Yuzhuo Wang
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada; The Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver BC, Canada.
| | - Cheryl D Helgason
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada.
| |
Collapse
|
8
|
Fazio N, Biffi R, Maibach R, Hayoz S, Thierstein S, Brauchli P, Bernhard J, Stupp R, Andreoni B, Renne G, Crosta C, Morant R, Chiappa A, Luca F, Zampino M, Huber O, Goldhirsch A, de Braud F, Roth A, Pace U, Cenciarelli S, Pozzi S, Bertani E, Mura S, Lorizzo K, Di Meglio G, Ravizza D, Boselli S, Matter M, Richter M, Monfardini S, Dittrich C, Häfner M, Clemens M. Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. Ann Oncol 2016; 27:668-673. [DOI: 10.1093/annonc/mdv620] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/29/2023] Open
|
9
|
Gautschi O, Stadelmann C, Aebersold-Keller F, König K, Büttner R, Heukamp LC, Betticher D, Baumann C, Buser K, Calderoni A, Casty A, DʼAddario G, Irlé C, Mamot C, Morant R, Trojan A, Pellicioli E, Jehle-Schwertfeger S, Aebi S, Diebold J. Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. Oncol Res Treat 2015; 38:560-9. [DOI: 10.1159/000441367] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Accepted: 10/01/2015] [Indexed: 11/19/2022]
|
10
|
Miller K, Morant R, Stenzl A, Zuna I, Wirth M. A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium. Urol Int 2015; 96:5-13. [PMID: 26068576 DOI: 10.1159/000381589] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 03/10/2015] [Indexed: 11/19/2022]
Abstract
INTRODUCTION This phase II trial evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, in combination with first-line chemotherapy in advanced urothelial cancer. METHODS Chemotherapy-naïve patients with advanced or metastatic urothelial carcinoma were randomized 1:1:1 to receive six cycles of chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 70 mg/m2 on day 1 of every cycle) concomitantly with gefitinib 250 mg/day (arm A); or with sequential gefitinib (arm B); or alone (arm C). The primary endpoint was the time to progression (TTP). RESULTS A total of 105 patients received study treatment. Median TTP for arms A, B, and C were 6.1, 6.3, and 7.8 months, respectively. There were no significant differences between treatment arms for any outcomes measured. The most common adverse events were nausea and vomiting. CONCLUSION Gefitinib in combination with chemotherapy did not improve efficacy in advanced urothelial cancer.
Collapse
Affiliation(s)
- Kurt Miller
- Department of Urology, University Hospital Charitx00E9;, Berlin, Germany
| | | | | | | | | |
Collapse
|
11
|
Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Lam WL, Farrar WL, Isogai T, Morant R, Castori-Eppenberger S, Chi KN, Wang Y, Helgason CD. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 2015; 5:764-74. [PMID: 24519926 PMCID: PMC3996663 DOI: 10.18632/oncotarget.1769] [Citation(s) in RCA: 181] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding RNAs (lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic targets. We therefore performed RNA sequencing on paired metastatic/non-metastatic PCa xenografts derived from clinical specimens. The most highly up-regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues (p<0.05) and up-regulated in PCa compared to 15 other neoplasms (p<0.001). Cancer-specific up-regulation of PCAT18 was confirmed on an independent dataset of PCa and benign prostatic hyperplasia samples (p<0.001). PCAT18 was detectable in plasma samples and increased incrementally from healthy individuals to those with localized and metastatic PCa (p<0.01). We identified a PCAT18-associated expression signature (PES), which is highly PCa-specific and activated in metastatic vs. primary PCa samples (p<1E-4, odds ratio>2). The PES was significantly associated with androgen receptor (AR) signalling. Accordingly, AR activation dramatically up-regulated PCAT18 expression in vitro and in vivo. PCAT18 silencing significantly (p<0.001) inhibited PCa cell proliferation and triggered caspase 3/7 activation, with no effect on non-neoplastic cells. PCAT18 silencing also inhibited PCa cell migration (p<0.01) and invasion (p<0.01). These results position PCAT18 as a potential therapeutic target and biomarker for metastatic PCa.
Collapse
Affiliation(s)
- Francesco Crea
- Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Morant R. The 9th International MASCC Symposium Supportive Care in Cancer, 26 February to 1 March 1997, St. Gallen, Switzerland. Support Care Cancer 2014. [DOI: 10.1007/s005200050103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Eppenberger-Castori S, Morant R, Diener PA, Fuerstenberger G, Horica C, Németh TAMAS, Sulmoni M, Eppenberger U, Vuaroqueaux V. Abstract 3470: Differential expression of angiogenesis and hypoxia in benign hyperplasia and cancer of the prostate. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-3470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction. Targeting tumour angiogenesis, lymphoangiogenesis and hypoxia mechanisms as well as anti-inflammatory agents are promising therapeutic strategies for the treatment of also prostate cancer (PCA). A key regulator in the adaptation to hypoxic situations occurring when tumors outgrow is the transcriptional activator hypoxia-inducible factor I (HIF1), which increases when oxygen pressure drops. To gain access to adequate supply of oxygen and nutrients, tumor and stroma cells can release mediators to induce migration and proliferation of endothelial cells resulting in the formation of new blood vessels. To monitor such interactions in human, we assessed selected genes expressions in benign prostatic hyperplasia (BPH), in several stages of PCA as well as in paired non-malignant prostatic and seminal vesicle specimens.
Patients and methods. The quantitative expression levels of selected genes representative for these pathways were assessed by real time PCR in a total of 170 samples obtained from patients with BPH and PCA. Tissue samples from the 122 PCA patients, which underwent radical prostatectomy, included 26 focal and 90 diffuse PCA with known pathological staging, 6 BPH, 13 paired non-malignant adjacent prostate and 24 seminal vesicles.
Results Nonparametric correlation comparison and unsupervised hierarchical clustering revealed that BPH expressed significantly higher transcript levels of HIF1, ETS1, Vascular Endothelial Growth Factor A, VEGFB, VEGFC, FIGF, FLT1, KDR, Adrenomedullin, IL 6 and its receptor IL6R, Insulin Growth Factor 1 and IGF2, MMP2 and TGFR2 as compared to PCA. Though sporadically high values of such factors occurred in some PCA, no significant correlation was found between the levels of these transcripts and the Gleason grade or the tumor size. Intermediate (between the one of BPH and of PCA) transcripts levels were often found in adjacent non-malignant prostate tissue. Of interest, VEGFA, FIFG and HIF1 high levels were also observed in the seminal vesicles of patients with PCA. Moreover, cyclooxygenase 2 (COX2) transcripts were found distinctly (100 fold) higher in the seminal vesicle specimens as compared to all other samples.
Discussion. Key players in angiogenesis and hypoxia pathways have been used for the successful development of drug target therapies. Yet, the same markers revealed to have poor diagnostic and predictive values. In our study we demonstrated that such molecules are differentially expressed in benign hyperplasia as compared to PCA independently of the Gleason grade and tumor size. It is therefore possible that angiogenesis would be differentially regulated under hypoxic or inflammatory conditions also involving other molecules and could influence metastatic dissemination at early steps of the tumor progression while the majority of tumors would continue growing under minimal vascular supply.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3470. doi:10.1158/1538-7445.AM2011-3470
Collapse
Affiliation(s)
| | - Rudolf Morant
- 2Brust- und Tumorzentrum ZeTuP, St.Gallen, Chur und Rapperswil, Switzerland
| | | | | | | | - TAMAS Németh
- 4Hirslanden Klinik Stephanshorn, St. Gallen, Switzerland
| | - Mauro Sulmoni
- 4Hirslanden Klinik Stephanshorn, St. Gallen, Switzerland
| | | | | |
Collapse
|
14
|
Morant R, Vuaroqueaux V, Diener PA, Fürstenberger G, Horica C, Németh T, Sulmoni M, Eppenberger U, Eppenberger-Castori S. Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR. Int J Clin Pharmacol Ther 2011; 49:86-87. [PMID: 21176740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Affiliation(s)
- R Morant
- Brust- und Tumorzentrum ZeTuP St. Gallen, Chur und Rapperswil,Switzerland.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Morant R, Sehrt D, Jaehde U. The 8th annual meeting of CESAR in St. Gallen--novel therapeutic concepts in hemato-oncology. Int J Clin Pharmacol Ther 2011; 49:58-59. [PMID: 21176728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
|
16
|
Affiliation(s)
- H J Senn
- Tumor and Breast Center ZeTuP, St Gallen, Switzerland
| | | |
Collapse
|
17
|
Morant R. [Principle and practice of clinical phase III studies]. Onkologie 2008; 31 Suppl 2:53-57. [PMID: 18487870 DOI: 10.1159/000113032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Randomized phase III studies compare new treatments with standard therapy according to defined guidelines and legal rules. Large international randomized phase III studies are some of the most complex and expensive medical experiments. The results of such trials will decide about the future of new drugs and are the basis of evidence-based medicine and the development of clinical guidelines. This contribution discusses randomization, endpoints, inclusion and exclusion criteria of phase III trials as well as further challenges when developing and conducting phase III studies in oncology.
Collapse
Affiliation(s)
- Rudolf Morant
- Tumorzentrum ZeTuP St.Gallen und Chur, St. Gallen, Schweiz.
| |
Collapse
|
18
|
Münger-Beyeler C, Bernhard J, Rufibach K, Morant R, Schmid HP. Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience. Support Care Cancer 2007; 16:461-7. [PMID: 17909864 DOI: 10.1007/s00520-007-0335-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2007] [Accepted: 09/05/2007] [Indexed: 10/22/2022]
Abstract
GOALS OF WORK The aim of this study was to evaluate pain intensity and the application of the WHO guidelines for cancer pain treatment in patients with prostate cancer treated at Swiss cancer centers. MATERIALS AND METHODS We analyzed a series of five multicenter phase II clinical trials which examined the palliative effect of different chemotherapies in patients with advanced hormone-refractory prostate carcinoma. Of 170 patients, 1,018 visits were evaluable for our purpose, including ratings of pain intensity by patients and prescribed analgesics. MAIN RESULTS No or mild pain was indicated by patients in 36 to 55% of the visits, more than mild pain in 30 to 46%. In 21% of the visits, the WHO pain treatment criteria (treatment according to one of the three steps; oral, rectal or transdermal application of the main dose; administration on a regular schedule) were fulfilled, and the Cleeland index was positive according to all recommendations. In 6% of the visits, neither the WHO criteria were fulfilled nor was the Cleeland index positive. This indicates insufficient pain treatment not following the WHO guidelines and that the prescribed analgesics were not sufficiently potent for the rated pain intensity. CONCLUSIONS In this selective Swiss sample, the standard of analgesic treatment is high. However, there is still scope for improvement. This cannot solely be solved by improving the knowledge of the physicians. Programs to change the patients' attitude towards cancer pain, training to improve the physicians' communication skills, and institutional changes may be promising strategies.
Collapse
Affiliation(s)
- C Münger-Beyeler
- Department of Internal Medicine, Bürgerspital, Schöngrünstrasse 38a, 4500, Solothurn, Switzerland.
| | | | | | | | | |
Collapse
|
19
|
Salzberg M, Rochlitz C, Morant R, Thalmann G, Pedrazzini A, Roggero E, Schönenberger A, Knuth A, Borner M. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Oncol Res Treat 2007; 30:355-60. [PMID: 17596743 DOI: 10.1159/000102452] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Prostate cancer is the most common type of cancer in men, however, therapeutic options are limited. 50-90% of hormone-refractory prostate cancer cells show an overexpression of epidermal growth factor receptor (EGFR), which may contribute to uncontrolled proliferation and resistance to chemotherapy. In vitro, gefitinib, an orally administered tyrosine kinase inhibitor, has shown a significant increase in antitumor activity when combined with chemotherapy. PATIENTS AND METHODS In this phase II study, the safety and efficacy of gefitinib in combination with docetaxel, a chemotherapeutic agent commonly used for prostate cancer, was investigated in patients with hormone-refractory prostate cancer (HRPC). 37 patients with HRPC were treated continuously with gefitinib 250 mg once daily and docetaxel 35 mg/m2 i.v. for up to 6 cycles. PSA response, defined as a =50% decrease in serum PSA compared with trial entry, was the primary efficacy parameter. PSA levels were measured at prescribed intervals. RESULTS The response rate and duration of response were consistent with those seen with docetaxel monotherapy. The combination of docetaxel and gefitinib was reasonably well tolerated in this study. CONCLUSION Future studies should investigate whether patients with specific tumor characteristics, e.g. EGFR protein overexpression, respond better to gefitinib than patients without, leading to a more customized therapy option.
Collapse
|
20
|
Sirbu D, Oprean C, Negru S, Draganescu M, Valeanu V, Reichert D, Eder S, Moritz B, Edler L, Morant R. P144 CELER: an international randomized phase III trial of the CESAR Group – or: Should chemotherapy be added to hormonal therapy in advanced breast cancer? Breast 2007. [DOI: 10.1016/s0960-9776(07)70204-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
21
|
Salzberg M, Borner M, Bauer JA, Morant R, Rauch D, Rochlitz C. Trastuzumab (Herceptin®) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur J Cancer 2006; 42:2660-1. [PMID: 16934972 DOI: 10.1016/j.ejca.2006.06.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2006] [Accepted: 06/23/2006] [Indexed: 11/28/2022]
|
22
|
Vuaroqueaux V, Diener P, Eppenberger-Castori S, Labuhn M, Horica C, Németh T, Sulmoni M, Fürstenberger G, Eppenberger U, Morant R. Molecular profiles of prostate cancer versus today’s diagnostic tools. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14659 Background: Tumor size, nodal status, the Gleason grading system and serum PSA values are today’s available prognostic tools of localized prostate cancer and the only help for adjuvant therapy. Based on the results of a feasibility study we continued the evaluation of the recently developed prognostic molecular signature. Methods: Of 60 CaP patients, who underwent primary prostatectomy in 2003 to 2005, fresh frozen samples of the tumor were asserved. The RNA extracted from cryocuts was tested. The quantitative RNA expression levels of 90 relevant genes involved in the different tumor hallmarks were simultaneously assessed. Results: Unsupervised agglomerative clustering of the obtained molecular profiles revealed different signatures. Correlations between these groups and the known TNM staging as well as Gleason scores were strongly present. Of interest was that all recurrences observed within this short period of time were found in a single cluster expressing higher levels of proliferation markers. Conclusions: The molecular profile of primary prostate cancer by quantitative RT-PCR is a powerful tool describing the biology of an individual tumor. Gene expression profiling can be precisely quantified and seems to be better reproducible than pathological judgments of the Gleason scores. Moreover, the gene panel is partially based on drug target genes and therefore of predictive value. Finally the method could be applied also in core biopsies. [Table: see text]
Collapse
Affiliation(s)
- V. Vuaroqueaux
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - P. Diener
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - S. Eppenberger-Castori
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - M. Labuhn
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - C. Horica
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - T. Németh
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - M. Sulmoni
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - G. Fürstenberger
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - U. Eppenberger
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| | - R. Morant
- OncoScore, Riehen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland; Klinik Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland
| |
Collapse
|
23
|
Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Dieterich H, Ehret S, Fürstenberger G, Morant R, Eppenberger U, Eppenberger-Castori S. Different prediction of distant recurrence risk in primary breast cancer patients stratified by ER and ERBB2 status. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20120 Background: Molecular profiling recently defined biological characteristics of several long-recognized breast cancer subtypes including ER-positive (luminal subtype), ER-negative/ERBB2-positive (ERBB2 subtype) and ER-negative/ErBB2-negative (basal-like subtype). Each of these particular subtypes has different impact on patient outcome and should be therefore taken in consideration for individual scoring calculations. Methods: The quantitative RNA expression levels of 70 relevant genes were simultaneously determined in fresh frozen samples of 317 primary breast cancer (BC) patients comprehending ER-positive (70%), ER-negative/ERBB2-positive (15%) and ERBB2-negative/ER-negative (15%) and with known follow-up data. Five years distant recurrence scoring systems were calculated by means of Cox-hazard regression models. Results: Two main prognostic scoring systems were developed: one based on genes relative to proliferation representing tumor growth and its velocity, the other based on proteases. A low proliferation score identified 30% of patients at very good prognosis (probability of distant recurrence 12%, CI: 1.5–22%) all belonging to the ER-positive subcategory as compared to cases with higher proliferation (probability of distant recurrence 31%, 32–38%). The probability to develop distant recurrence within 5 years for 30% of ERBB2-positive patients was of only 12% (CI 0–25%) when accompanied by low levels of proteases as compared to the remaining ERBB2-positive patients with a probability of recurrence of 40% (CI 22–54%). Conclusions: ER, ERBB2 and the expression levels of the few identified genes involved in tumor proliferation and invasion can be easily and precisely detected by means of QRT-PCR. This robust method allows fine tuned prognosis and gives predictive information for the treatment of individual breast cancer. [Table: see text]
Collapse
Affiliation(s)
- P. Urban
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - V. Vuaroqueaux
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - M. Labuhn
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - M. Delorenzi
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - P. Wirapati
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - H. Dieterich
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - S. Ehret
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - G. Fürstenberger
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - R. Morant
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - U. Eppenberger
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| | - S. Eppenberger-Castori
- Stiftung Tumorbank Basel, Riehen, Switzerland; OncoScore, Riehen, Switzerland; ISREC, NCCR, Lausanne, Switzerland; Frauenklinik Rheinfelden, Rheinfelden, Germany; ZeTuP, St. Gallen, Switzerland
| |
Collapse
|
24
|
Glaus A, Boehme C, Thürlimann B, Ruhstaller T, Hsu Schmitz SF, Morant R, Senn HJ, von Moos R. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006; 17:801-6. [PMID: 16507565 DOI: 10.1093/annonc/mdl030] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Hormonal treatment for women with breast cancer is frequently proposed in the adjuvant as well as in the palliative setting. Therefore, many women are confronted with early menopause and prolonged oestrogen deprivation and consequently with a variety of quality of life issues, such as menopausal symptoms and fatigue. PATIENTS AND METHODS It was the aim of this study to explore the occurrence and frequency of menopausal symptoms in women with breast cancer, undergoing hormonal cancer treatment and to investigate their relationship with fatigue. A cross-sectional, quantitative approach was used in this multi-centre study. The Checklist for Patients with Endocrine Therapy (C-PET) and the International Breast Cancer Study Group (IBCSG) Linear Analogue Scales for patients with endocrine treatment were used. Descriptive statistics, as well as cluster analyses were performed. RESULTS Most frequent menopausal symptoms involved hot flashes/sweats, tiredness, weight gain, vaginal dryness and decreased sexual interest. There were significant differences between the fatigued and the non-fatigued population regarding the intensity of menopausal symptoms, emotional irritability and general coping. Cluster analyses supported a menopausal symptom cluster. CONCLUSIONS Fatigue accompanies menopausal symptoms and an association can be expected. Methods for routine screening for menopausal symptoms, including fatigue, are suggested as a relevant research issue in women with breast cancer undergoing hormonal treatment.
Collapse
Affiliation(s)
- A Glaus
- Tumorzentrum ZeTuP, Diagnostik, Behandlung und Prävention, St. Gallen, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Fürstenberger G, Senn E, Morant R, Bolliger B, Senn HJ. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 2006; 15:64-8. [PMID: 15998587 DOI: 10.1016/j.breast.2005.04.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2004] [Revised: 03/23/2005] [Accepted: 04/08/2005] [Indexed: 11/26/2022] Open
Abstract
High serum concentrations of insulin-like growth factor-1 (IGF-1) are associated with an increased risk of breast, prostate, colorectal, and lung cancer whereas IGF binding protein-3 (IGFBP-3) seems to exert a protective effect. Therefore, patients may benefit from low IGF-1 levels and high IGFBP-3 levels. This study evaluated whether adjuvant anthracycline-containing chemotherapy modulates IGF-1 and/or IGFBP-3 serum levels in breast cancer patients. In 18 patients undergoing adjuvant treatment for primary breast cancer, IGF-1 and IGFBP-3 serum levels were measured with immunoassays during chemotherapy regimens of either 5-fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC). Mean pre-treatment values of IGF-1 and IGFBP-3 were 124+/-13 and 3698+/-186 ng/ml, respectively. No significant changes in IGF-1 and IGFBP-3 serum concentrations were observed during adjuvant anthracycline-containing chemotherapy. IGF-1 levels significantly correlated with IGFBP-3 levels before and during chemotherapy. In conclusion, these chemotherapy regimens do not seem to modulate IGF-1 or IGFBP-3 levels in a favourable or unfavourable way.
Collapse
Affiliation(s)
- Gregor Fürstenberger
- Center for Tumor Detection and Prevention, Rorschacherstrasse 150, CH-9006 St. Gallen, Switzerland.
| | | | | | | | | |
Collapse
|
26
|
Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tarkovács G, Linkesch W, Maniatis A, Morant R, Drach J, Kuhn I, Schuster J, Hinke A. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. Br J Haematol 2005; 131:329-37. [PMID: 16225652 DOI: 10.1111/j.1365-2141.2005.05779.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
We report on a randomised trial that aimed to compare the efficacy of continued daily prednisolone treatment during the entire induction phase, with prednisolone given for 2 weeks of each cycle in combination with VMCP (vincristine, melphalan, cyclophosphamide, prednisolone)-interferon-alpha 2b (IFN-alpha 2b) treatment in 299 previously untreated elderly patients (median age: 67 years) with multiple myeloma. After completion of induction treatment patients were randomised to IFN-alpha 2b with or without prednisolone, thrice weekly. Response rate was 62% in the continuous and 60% in the control arm (intent to treat analysis, P=0.81). Progression-free survival [median: 20 months vs. 19 months; hazard ratio (HR): 0.99, 95% confidence interval (CI): 0.74-1.33, P=0.97] and overall survival (median: 34 months vs. 37 months; HR: 1.16, 95% CI: 0.85-1.59, P=0.35) were similar in both groups. Reduced performance status (Eastern Cooperative Oncology Group, grades 2-4) was the predominant risk factor for poor survival followed by age >65 years, high beta2-microglobulin, and impaired renal function. There was more grades 3-4 dyspnoea and cardiac impairment and grades 1-2 hyperglycaemia, but less nausea, emesis and anaemia in patients on continuous prednisolone therapy. In conclusion, continuing prednisolone treatment during the entire duration of the induction phase with VMCP-IFN-alpha 2b did not improve outcome.
Collapse
Affiliation(s)
- Heinz Ludwig
- Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 2005; 57:533-9. [PMID: 16052341 DOI: 10.1007/s00280-005-0070-z] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2005] [Accepted: 06/22/2005] [Indexed: 11/25/2022]
Abstract
Epidermal growth factor receptor (EGFR) expression has been associated with clinical outcome in some studies of renal-cell carcinoma (RCC). We investigated the efficacy and safety of gefitinib (IRESSA), an EGFR tyrosine kinase inhibitor, in RCC patients. This phase II trial recruited 28 patients with advanced, metastatic, or relapsed RCC. Patients received oral gefitinib 500 mg/day. Objective responses (ORs) were assessed every 2 months according to RECIST. Baseline tumor biopsies were analyzed immunohistochemically for EGFR expression. At trial closure (March 2003), no ORs were seen but 14 patients (53.8%) had stable disease. At extended analysis (August 2004), median time to progression was 110 days (95% confidence interval [CI]: 55, 117); median overall survival was 303 days (95% CI 180, 444). Gefitinib was generally well tolerated. Skin rash and diarrhea were the most common drug-related adverse events (AEs) [54 and 39% of patients, respectively] and the most common drug-related grade 3/4 AEs (both 11%). The majority of tumor biopsies (91%) had > or =70% of tumor cells expressing membrane EGFR. Despite the lack of ORs in this study, disease control was observed in 53.8% of patients. Gefitinib was generally well tolerated and no unexpected drug-related AEs were observed.
Collapse
Affiliation(s)
- Monika Jermann
- Clinic and Policlinic of Oncology, University Hospital, Zurich, Switzerland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Vuaroqueaux V, Labuhn M, Morant R, Diener PA, Horica C, Németh T, Sulmoni M, Urban P, Fürstenberger G, Eppenberger U, Eppenberger-Castori S. Molecular profiles of prostate cancer and its surrounding non-malignant tissue. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- V. Vuaroqueaux
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - M. Labuhn
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - R. Morant
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - P. A. Diener
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - C. Horica
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - T. Németh
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - M. Sulmoni
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - P. Urban
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - G. Fürstenberger
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - U. Eppenberger
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| | - S. Eppenberger-Castori
- OncoScore, Riehen, Switzerland; ZeTuP and Klin Stephanshorn, St. Gallen, Switzerland; Pathology Institute, St. Gallen, Switzerland; Klin Stephanshorn, St. Gallen, Switzerland; ZeTuP, St. Gallen, Switzerland; OncoScore and Stiftung Tumorbank Basel, Riehen, Switzerland; Stiftung Tumorbank Basel, Riehen, Switzerland
| |
Collapse
|
29
|
Seium Y, Stupp R, Ruhstaller T, Gervaz P, Mentha G, Philippe M, Allal A, Trembleau C, Bauer J, Morant R, Roth AD. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study. Ann Oncol 2005; 16:762-6. [PMID: 15817597 DOI: 10.1093/annonc/mdi154] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC). PATIENTS AND METHODS CRC patients not pretreated with palliative chemotherapy, with performance status < or =1 and adequate haematological, kidney and liver function, were eligible. Treatment consisted in weekly 24-h infusion 5-FU (2300 mg/m(2))/LV (30 mg) and alternating OHP (70-85 mg/m(2), days 1 and 15) and CPT-11 (80-140 mg/m(2), days 8 and 22) repeated every 5 weeks. OHP and CPT-11 were escalated in cohorts of three to six patients. RESULTS Thirty patients received a median of five cycles. Dose-limiting toxicity occurred at dose level 3, and the recommended dose was OHP 70 mg/m(2), CPT-11 100 mg/m(2), LV 30 mg and 5-FU 2300 mg/m(2)/24 h. Grade > or =3 toxicities were diarrhea 23%, neutropenia 20%, fatigue 7%, and neurologic 7%. Two febrile neutropenia episodes (one fatal) were recorded. Among 28 patients with measurable disease (90%), we observed two complete and 20 partial responses; overall RR was 78% (95% CI, 59% to 92%). Median time to progression and overall survival were 9.5 and 25.4 months, respectively. Seven patients underwent liver metastases resection. CONCLUSION OCFL is an overall well tolerated regimen with very high efficacy, which makes it most suitable for tumour control before surgery of metastatic disease.
Collapse
Affiliation(s)
- Y Seium
- Oncosurgery, Services of Visceral Surgery and Radiooncology, Geneva University Hospital, Geneva, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 2005; 92:1055-62. [PMID: 15756271 PMCID: PMC2361950 DOI: 10.1038/sj.bjc.6602462] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Although irinotecan 350 mg m−2 is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU). This study assessed the optimal dosing strategy for irinotecan, along with treatment efficacy and safety. A total of 164 patients with metastatic colorectal cancer progressing after failure on 5-FU or raltitrexed received either 350 mg m−2 irinotecan (Group A; n=36) or 250, 350 or 500 mg m−2, according to individual patient tolerance (Group B; n=62) or based on risk factor optimisation (Group C; n=66). There were no complete responses. There was a trend towards a higher overall response rate in Group B (13%) than in Groups A (8%) and C (9%). Tumour control growth rate was high in all three groups: 58% in group A, 60% in Group B and 50% in Group C. A total of 34% of patients in Group B and 9% in Group C were able to receive a dose of 500 mg m−2. Median duration of response and time to progression were significantly longer in Groups A and B compared with Group C. No significant between-group differences for any adverse events were seen, although there was a small trend towards better tolerability in Group B. Individual dose escalation based on patient tolerance may allow more patients to receive a higher irinotecan dose without causing additional toxicity and can be an appropriate patient management strategy.
Collapse
Affiliation(s)
- E Van Cutsem
- University Hospital Gasthuisberg, 3000 Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, de Braud F. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol 2004; 15:759-64. [PMID: 15111343 DOI: 10.1093/annonc/mdh187] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND A phase I-II multicenter trial was conducted to define the maximum tolerated dose (MTD) according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of response and survival (secondary objectives), of a combination of 5-fluorouracil (5-FU) in protracted continuous intravenous infusion (p.i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer. PATIENTS AND METHODS Patients with measurable unresectable and/or metastatic gastric carcinoma, World Health Organization performance status < or =1, normal hematological and renal functions, adequate hepatic function and not pretreated for advanced disease by chemotherapy, received up to eight cycles of a combination of docetaxel on day 1, cisplatin on day 1 and 5-FU p.i.v. on days 1-14 (TCF) every 3 weeks, which was escalated up to the MTD, defined by the occurrence of dose-limiting toxicity in two patients in one dose level. RESULTS Fifty-two patients were accrued and treated (43 in the phase I part of the trial and nine additional at the recommended dose level). A median of five cycles/patient was given. The recommended dose of TCF was docetaxel 85 mg/m(2) on day 1, cisplatin 75 mg/m(2) on day 1 and 5-FU p.i.v. 300 mg/m(2)/day on days 1-14. Grade > or =3 toxicities were neutropenia 79%, alopecia 46%, fatigue 23%, mucositis 10%, diarrhea 19%, nausea/vomiting 13%, neurological 4% and palmar-plantar 2%. Ten non-fatal febrile neutropenia episodes were recorded in eight patients. There were no treatment-related deaths. Among 41 patients with measurable disease (79%), we observed one complete and 20 partial responses for an overall intent-to-treat response rate of 51% (95% confidence interval 35-67%). Five patients (20%) had stable disease for > or =12 weeks (four cycles). The median overall survival was 9.3 months. CONCLUSIONS 5-FU p.i.v. at 300 mg/m(2)/day for 2 weeks out of three could be safely added to the docetaxel-cisplatin (TC) combination, but the dose of docetaxel had to be reduced to 75 mg/m(2) in a subsequent phase II trial. This drug regimen seems to be very active in advanced gastric cancer. Comparison with both TC and ECF in a randomized SAKK trial is ongoing.
Collapse
Affiliation(s)
- A D Roth
- Oncosurgery, Department of Surgery, Hôpital Cantonal Universitaire/Geneva University Hospital, 24 Micheli-du-Crest, CH-12ll Geneva 14, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Glaus A, Knipping C, Morant R, Böhme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Hüsler A, Deuson R. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004; 12:708-15. [PMID: 15278682 DOI: 10.1007/s00520-004-0662-x] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
GOALS OF WORK The aim of this study was to evaluate the occurrence of chemotherapy-induced nausea and vomiting (CINV) and its effect on patients' ability to carry out daily life activities following moderately to highly emetogenic, first-cycle chemotherapy in routine practice in cancer centers of four different European countries. PATIENTS AND METHODS This was a prospective, cross-sectional, nonrandomized, self-assessment study in 249 patients enrolled from cancer centers in Spain, Austria, Germany, and Switzerland. The study population consisted of 78% women, with a mean age of 54. Breast, lung, and ovarian cancers made up 75% of all cancers in the study. Patients received a mean of 2.0 chemotherapy agents and 2.5 antiemetic drugs. MAIN RESULTS A total of 450 emetic episodes experienced by 243 patients was recorded over 5 days following chemotherapy, with an average of 1.8 episodes per patient (range: 0-28). A higher percentage of patients (38%) suffered from delayed compared to acute emesis (13%). Between 42% and 52% of all patients suffered from nausea (visual analogue scale > or = 5 mm) on any one day, peaking at day 3. Using the Functional Living Index for Emesis (FLIE) questionnaire, 75% of patients with nausea and 50% with vomiting reported a negative impact of these conditions on performance of daily living. CONCLUSIONS CINV remains a significant problem in routine practice, particularly in the delayed phase posttreatment. Overall, CINV had a negative impact on patients' daily life.
Collapse
Affiliation(s)
- Agnes Glaus
- Zentrum für Tumordiagnostik und Prävention, Rorschacher Strasse 150, 9006 St. Gallen, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Morant R, Bernhard J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J, Cerny T, Rochlitz C, Wernli M, Gschwend A, Hanselmann S, Hering F, Schmid HP. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer 2004; 90:1312-7. [PMID: 15054447 PMCID: PMC2409680 DOI: 10.1038/sj.bjc.6601673] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile. In all, 25 patients with HRPC were enrolled on a phase II trial of capecitabine (Xeloda) at a dose of 1250 mg m(-2) orally twice daily on days 1-14 every 21 days. The inclusion criteria were PSA serum levels >3 x upper limit of normal, a WHO performance status 0-2, age <85 years and adequate bone marrow, liver and renal function. In patients with grade 2 or higher haematological toxicity on day 1 of the treatment cycle, therapy was first delayed, and then continued at a lower dose. Trial end points were PSA response and clinical benefit defined by quality of life (QL) data and analgesic consumption. The median age of patients was 70 years (range 54-85 years). A median of three cycles of capecitabine was administered (range 1-8). PSA response was observed in three patients (12%, 95% CI 3-31%), with times to tumour progression of 18, 21 and 35 weeks, respectively. In these patients, the response durations were 12, 17 and 32 weeks, respectively. Minor PSA regression was also seen in two further patients. The median time to tumour progression of all patients was 12 weeks (95% CI 9-15 weeks). Haematological toxicity was minor, with leukopenia grade 3 observed in one patient. There were three deaths during trial treatment, respectively, due to sepsis following mucositis and leukopenia, presumed sepsis with mucositis induced by chemotherapy and concomitant radiotherapy and cerebral dysfunction progressing to coma. Hand-foot syndrome grades 2 and 3 were observed in four patients each. Clinical benefit was observed in five patients (20%, CI 7-41%). Based on toxicity data, we recommend a lower starting dose of 1000 mg x m(-2) orally twice daily. While capecitabine has some activity in HRPC, as suggested by observed PSA responses, we conclude that it is not worthwhile to investigate capecitabine monotherapy in a phase III trial. Combinations of capecitabine with other agents, such as vinorelbine or docetaxel, may prove to be more effective.
Collapse
Affiliation(s)
- R Morant
- Zentrum für Tumordiagnostik und Prävention (ZeTuP), Rorschacherstrasse 150, St Gallen CH-9006, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Senn HJ, Morant R. Welcome to St. Gallen and Eastern Switzerland! EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90088-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
35
|
Abstract
The insulin-like growth factor (IGF) system performs multiple functions in normal tissue. IGFs are involved in normal mammary gland development, but have also been implicated in the pathogenesis of breast cancer. Epidemiological studies found an association between elevated serum levels of IGF-I and an increased risk for breast cancer. IGF-I is the major mediator of growth hormone (GH) action. On the cellular level, IGF-I has a strong influence on cell proliferation and it is a potent inhibitor of apoptosis. Further, IGFs are also involved in angiogenesis. These characteristics are the basis for their involvement in maintenance and progression of cancer. The functions of IGF-I are mainly mediated through the type-I IGF-receptor (IGF-IR). The availability of free IGF-I for interaction with IGF-IR is modulated by IGF binding proteins (IGFBP 1-6). Based on interactions with other receptors, including estrogen and epidermal growth factor receptors, combined targeted therapies may improve breast cancer treatment.
Collapse
Affiliation(s)
- G Fürstenberger
- Zentrum für Tumordiagnostik und Prävention, St. Gallen, Switzerland.
| | | | | |
Collapse
|
36
|
Fürstenberger G, Morant R, Bolliger B, Senn H. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 2003. [DOI: 10.1016/s0960-9776(03)80095-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
37
|
Abstract
OBJECTIVE In hormone refractory prostatic carcinoma (HRPCa), the majority of patients have bone metastases only, which are by definition non-measurable. This makes objective evaluation of chemotherapeutic agents difficult. Prostate specific antigen (PSA) as a dynamic model was analyzed as potential auxiliary end point in HRPCa. METHODS In the framework of a master protocol, the Swiss Group for Clinical Cancer Research (SAKK) is evaluating cytotoxic drugs in HRPCa since 1991. These prospective phase II trials include uniform requirements with regard to response, toxicity and quality of life. From the entire pool of patients, 40 with bidimensionally measurable metastases (lymph nodes, visceral organs) could be identified. PSA doubling time was calculated in patients with a rising PSA during therapy. RESULTS Objective best response to any given chemotherapeutic agent was: partial remission (PR) in six patients (15%), stable disease (SD) in 13 (32%) and progressive disease (PD) in 21 (53%). PSA remained stable or decreased in four of six patients with PR (67%), seven of 13 with SD (54%) but only in four of 21 with PD (19%) (Cochran-Armitage test for trend; p=0.015). The median PSA doubling time for patients with a rising PSA was 238 days in PR and 224 days in SD, compared to 113 days in PD (Wilcoxon test; p=0.002). CONCLUSIONS PSA doubling time is a potential auxiliary end point in the evaluation of cytotoxic drugs in HRPCa. Thus, also patients with non-measurable (bone) metastases could be included in analysis of response.
Collapse
|
38
|
Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003; 21:66-8. [PMID: 12506172 DOI: 10.1200/jco.2003.04.029] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
PURPOSE Preclinical studies indicate positive interactions between capecitabine, an oral fluorouracil precursor, and gemcitabine, the current standard treatment for advanced pancreatic carcinoma (APC). In this study, we investigated the addition of capecitabine to gemcitabine treatment for patients with APC. PATIENTS AND METHODS This multicenter study included patients naïve to chemotherapy who had histologically or cytologically confirmed, nonresectable or metastatic pancreatic carcinoma. Gemcitabine was given at a fixed dose of 1,000 mg/m(2) on days 1 and 8 of a 21-day cycle. Capecitabine was given in increasing doses orally bid for 14 days followed by a 1-week rest. The maximum-tolerated dose (MTD) was defined as one dose level below the dose causing dose-limiting toxicity (DLT) in >or= one third of a cohort of six patients. We included an additional 15 patients at the MTD. RESULTS Thirty-six patients were included. DLT occurred at a dose of 800 mg/m(2) bid of capecitabine and consisted of myelotoxicity and mucositis. Hand-foot syndrome was not observed, and other toxic effects were mild. Thus, in this regimen, the recommended dose of capecitabine is 650 mg/m(2) bid. In 27 patients with measurable disease, we observed one complete and four partial remissions. In addition, significant drops (> 50% from baseline value) of the tumor marker CA 19-9 occurred in 14 of 24 assessable patients. CONCLUSION The combination of capecitabine and gemcitabine is well tolerated, with apparent efficacy in patients with APC. Therefore, it is currently being compared with gemcitabine monotherapy in a phase III study.
Collapse
|
39
|
Morant R, Hsu Schmitz SF, Bernhard J, Thürlimann B, Borner M, Wernli M, Egli F, Forrer P, Streit A, Jacky E, Hanselmann S, Bauer J, Hering F, Schmid HP. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. Eur J Cancer 2002; 38:1626-32. [PMID: 12142053 DOI: 10.1016/s0959-8049(02)00145-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The purpose of this study was to evaluate the efficacy of vinorelbine treatment in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score for the subgroup of patients with pain), as well as its toxicity in patients with progressive metastatic androgen-independent prostatic carcinoma. 44 patients with prostatic carcinoma progressing after orchiectomy or during treatment with hormonal agents were treated with vinorelbine at a dose of 30 mg/m(2) intravenously (i.v.) on days 1 and 8 of a 21-day cycle. Inclusion criteria were metastatic progressive prostatic carcinoma with prostate-specific antigen (PSA) serum levels >/=3 x upper limit of normal, World Health Organization (WHO) performance status </=2, age <85 years and adequate bone marrow, liver and renal functions. Treatment was continued until progression or a maximum of 12 cycles. Treatment was delayed for a week if haematological toxicity grade >/=2 was observed on the day of scheduled vinorelbine administration. 9 patients received less than three cycles, 6 due to rapid tumour progression. Treatment at day 1 had to be delayed in 13.7% of 183 cycles. Treatment at day 8 had to be omitted in 19.7% of all cycles. Grade >/=3 granulocytopenia occurred in 18% of patients. 4 patients had severe constipation. In 7 patients (15.9%, Confidence Interval (CI) 6.6-30.1%), a PSA response (>/=50% reduction of PSA levels) was observed. Among 8 patients with measurable disease, 3 had partial remission and 1 no change. Median time to PSA progression in 43 assessable patients was 11.9 weeks (range 3-52 weeks). Median duration of PSA response was 14 weeks (9-30 weeks). Clinical benefit was seen in 7 of 31 cases (23%) with baseline pain, there was no association with PSA response. Vinorelbine is a fairly well tolerated drug with a moderate single agent activity in patients with androgen-refractory prostate cancer.
Collapse
Affiliation(s)
- R Morant
- Zentrum für Tumordiagnostik and Prävention (ZeTuP), Rorschacherstrasse 150, CH-9006, St. Gallen, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Tumor Prevention and Genetics 2002, the 2nd International Conference and 7th Annual Meeting of The International Society of Cancer Chemoprevention (ISCaC) was held in St. Gallen, Switzerland, 14-16 February 2002.
Collapse
Affiliation(s)
- Rudolf Morant
- ZeTuP, Rorschacherstrasse 150, 9006, St. Gallen, Switzerland.
| |
Collapse
|
41
|
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-66. [PMID: 11919232 DOI: 10.1200/jco.2002.07.087] [Citation(s) in RCA: 144] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer. PATIENTS AND METHODS Forty-three nonpretreated patients and 26 patients who had experienced one fluoropyrimidine-containing regimen for advanced colorectal cancer were treated with oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1,250 mg/m(2) bid on days 1 to 14 every 3 weeks. Patients with good performance status (World Health Organization grade 0 to 1) were accrued onto two nonrandomized parallel arms of a phase II study. RESULTS The objective response rate was 49% (95% confidence interval [CI], 33% to 65%) for nonpretreated and 15% (95% CI, 4% to 35%) for pretreated patients. The main toxicity of this combination was diarrhea, which occurred at grade 3 or 4 in 35% of the nonpretreated and 50% of the pretreated patients. Grade 3 or 4 sensory neuropathy, including laryngopharyngeal dysesthesia, occurred in 16% of patients on both cohorts. Capecitabine dose reductions were necessary in 26% of the nonpretreated and 45% of the pretreated patients in the second treatment cycle. The median overall survival was 17.1 months and 11.5 months, respectively. CONCLUSION Combining capecitabine and oxaliplatin yields promising activity in advanced colorectal cancer. The main toxicity is diarrhea, which is manageable with appropriate dose reductions. On the basis of our toxicity experience, we recommend use of capecitabine in combination with oxaliplatin 130 mg/m(2) at an initial dose of 1,250 mg/m(2) bid in nonpretreated patients and at a dose of 1,000 mg/m(2) bid in pretreated patients.
Collapse
|
42
|
D'Addario G, Morant R, Boehme C, Cerny T. Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors. Oncol Res Treat 2002; 25:152-7. [PMID: 12006766 DOI: 10.1159/000055225] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Chemotherapy with paclitaxel and carboplatin 3-weekly is active in many tumors. Major toxicities are myelosuppression and neurotoxicity. Weekly administration of taxanes allows high dose intensity with reduced toxicity. PATIENTS AND METHODS 131 patients with solid tumors were treated as outpatients with paclitaxel 75 mg/m(2) and carboplatin AUC 2-3 days 1, 8, 15 every 4 weeks irrespective of pretreatment and partly in neoadjuvant and multimodal concepts. RESULTS 125 patients (median age 58 years) were evaluable for response and toxicity, of whom 45 suffered esophageal carcinoma (19 patients in neoadjuvant treatment) and 31 non-small cell lung cancer. 49 patients were pretreated. 23 patients received concomitant radiotherapy of esophagus or lung in doses ranging from 40 to 60 Gy. We observed a low hematologic toxicity with 15.2% grade-III/IV leukopenia/granulocytopenia and 3.2% thrombocytopenia grade III/IV. Neurotoxicity grade II was reported in 14 patients. Main toxicity with radiotherapy was esophagitis grade II or III in 7 out of 23 patients. Overall response rate was 54.2%. 5 out of 19 patients treated neoadjuvantly for esophageal cancer reached a pathological complete response. CONCLUSIONS Weekly paclitaxel and carboplatin is safe and feasible in outpatients and a high dose intensity can be achieved. The favorable toxicity profile allows treatment of elderly and pretreated patients. Response rate is high including pathological complete responses and responses appear quickly, making this therapy most suitable for multimodal and neoadjuvant treatments.
Collapse
Affiliation(s)
- G D'Addario
- Fachbereich Onkologie/Hämatologie, Departement Innere Medizin, Kantonsspital, St. Gallen, Germany.
| | | | | | | |
Collapse
|
43
|
Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, Baudin M, Escudier B, Heinzerling L, Morant R, Herrmann R, Dietrich PY, Dummer R. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002; 9:289-95. [PMID: 11896446 DOI: 10.1038/sj.cgt.7700441] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2001] [Indexed: 02/05/2023]
Abstract
BACKGROUND Systemic IL-2 has shown some activity in metastatic melanoma, but its use is severely limited by toxicity. TG2001 is a product in which the human IL-2 cDNA was incorporated into the genome of Vero cells, a monkey fibroblast cell line. The goal of this intratumorally applied therapy was to create an antitumor immune response stimulated by xeno-antigens and local production of IL-2 in the close vicinity of tumor-specific antigens. TG2001 was reported to have a good safety profile in two previous dose-escalating phase I studies performed in 18 patients with various solid tumors, with encouraging clinical responses in three patients. The objectives of this study were to evaluate the tolerance and incidence of tumor regression in patients with metastatic melanoma, following repeated administration of Vero-IL-2 cells. PATIENTS AND METHODS This was on open-label, randomized phase II study comparing two doses of Vero-IL-2, 5x10(5) and 5x10(6) cells. Twenty-eight patients with metastatic melanoma were enrolled in the study, 14 in each treatment group. Patients received TG2001 by intratumoral injection on days 1, 3, and 5 every 4 weeks for four cycles, and every 8 weeks thereafter, until evidence of progressive disease (PD). Criteria for patient selection included histologically proven metastatic melanoma, with one tumor accessible for product administration, and at least another tumor site for response assessment. Evaluation included tumor measurements, humoral and T cell-mediated local and systemic immune response, humoral response to Vero cells, adverse events and standard laboratory parameters. RESULTS None of the patients achieved a confirmed objective response. Stable disease (SD) was seen in six (43%) and eight patients (57%) at the 5x10(5) and the 5x10(6) dose level, respectively. Two patients, one in each group, died during the study (i.e., within 1 month after the last injection) due to PD. Three patients exhibited antibody responses to Vero cells. T-cell immunity, serum cytokine levels and cytokine mRNA expression in tumor biopsies did not show meaningful alterations after therapy, except for a trend toward an increase in intratumoral TH2 cytokine (IL-4 and/or IL-10) levels. The study drug was well tolerated at both dose levels and side effects mainly consisted of injection site pain and erythema, and pyrexia. CONCLUSION The intratumoral administration of TG2001 was generally well tolerated in patients with metastatic melanoma, and transient disease stabilization was observed in 50% of patients.
Collapse
Affiliation(s)
- Christoph Rochlitz
- Departement Innere Medizin, Abteilung für Onkologie, Kantonsspital, Petersgraben 4, CH-4031 Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Morant R. The attitudes of primary care physicians practicing around the Lake of Constance towards the screening of common carcinomas. Eur J Cancer 2002. [DOI: 10.1016/s0959-8049(02)80034-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer 2001; 37:2194-8. [PMID: 11677106 DOI: 10.1016/s0959-8049(01)00286-6] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Two multicentre phase II trials were designed to determine if tumour responses can be achieved in progressive small-cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) patients treated with ISIS 5132, an inhibitor of C-raf kinase mRNA expression (CGP 69846A; ISIS Pharmaceuticals Inc, Carlsbad, CA), and to further characterise the safety of the compound. Between August 1998 and November 1999, 26 patients (18 NSCLC, 8 SCLC) were entered. Out of these, 23 were eligible, 22 (18 NSCLC, 4 SCLC) were treated with ISIS 5132 (2 mg/kg/day, 21 days continuous intravenous (i.v.) infusion every 4 weeks) and were evaluable for toxicity and 18 (15 NSCLC, 3 SCLC) were evaluable for efficacy. For the whole group haematological toxicity did not exceed grade 2. One patient experienced a grade 4 increased prothrombin time. Non-haematological toxicity was mild to moderate, with the observation of asthenia and nausea and vomiting. Progressive disease (PD) was diagnosed in 10 patients (8 NSCLC and 2 SCLC). 8 more patients (7 NSCLC, 1 SCLC) were considered as treatment failures. In conclusion, this study using ISIS 5132 with this dose and schedule of administration excludes a 20% response rate with 95% confidence intervals for NSCLC and cannot draw any conclusions for SCLC patients as only a few were involved in the study.
Collapse
Affiliation(s)
- B Coudert
- Centre GF Leclerc BP 77980, 21079 Dijon Cedex, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Surgical treatment of locally advanced gastric carcinoma still results in unsatisfactory survival results. The addition of adjuvant chemotherapy has been shown to be of little value and is not considered standard practice. Preoperative chemotherapy, however, has a strong theoretical basis and may achieve significant tumor shrinkage and downstaging and thus allow complete resection of cancers previously judged by the responsible surgeon to be inoperable. However, it has not yet been demonstrated whether preoperative chemotherapy prolongs the survival of patients with potentially resectable cancers. Based on theoretical reasons, preoperative chemotherapy may be expected to be more efficient than postoperative chemotherapy. Various phase II trials have shown the feasibility of this approach, and encouraging results were found. Differing diagnostic methods, inclusion criteria, and chemotherapy regimens hamper direct comparisons between the trials. Several useful new drugs including taxanes and camptothecins and promising chemotherapy regimens incorporating continuously infused 5-fluorouracil have been introduced recently. Ongoing large randomized clinical trials (MAGIC trial, EORTC, SAKK) currently study the efficacy of preoperative chemotherapy in locally advanced gastric carcinoma.
Collapse
Affiliation(s)
- R Morant
- Zentrum für Tumordiagnostik und Prävention, St. Gallen.
| |
Collapse
|
47
|
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol 2000; 46:167-71. [PMID: 10972487 DOI: 10.1007/s002800000134] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
PURPOSE In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. PATIENTS AND METHODS Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. The drug was given as a bolus infusion at a 4-weekly dose of 150 microg/m2. A total of 140 patients were entered and a total of 285 courses were administered. RESULTS In general, the compound was well tolerated. Myelotoxicity was the most common toxicity. Grade 3 and 4 leukopenia was observed in 18.6% of the courses, neutropenia in 20.3%, thrombocytopenia in 16.2% and anemia in 8.7%. Double nadirs were seen in a total of 41 courses for neutrophils, in 40 for leukocytes and in 3 for platelets. Non-hematological toxicity was very mild. Only one partial response in a patient with melanoma was seen. CONCLUSIONS At this dose and schedule carzelesin did not yield activity in the types of tumors studied.
Collapse
Affiliation(s)
- N Pavlidis
- Department of Medical Oncology, Medical School, University of Ioannina, Greece.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000; 11:301-6. [PMID: 10811496 DOI: 10.1023/a:1008342013224] [Citation(s) in RCA: 149] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
PURPOSE A multi-centric trial was performed to explore the clinical activity, in terms of response and toxicity (primary objectives), duration of response and survival (secondary objectives), of docetaxel with cisplatin in advanced gastric cancer (AGC). PATIENTS AND METHODS Patients with measurable unresectable and/or metastatic gastric carcinoma, performance status < or = 1, normal hematological, hepatic and renal functions and not pretreated for advanced disease by chemotherapy received up to eight cycles of TC (docetaxel 85 mg/m2 dl, cisplatin 75 mg/m2 dl) q3w. Dose escalation to 100 mg/m2 was performed in five patients and was discontinued for excessive toxicity. RESULTS Forty-eight patients were accrued. A median of 5 cycles/patient was given. We observed 2 complete and 25 partial responses for an overall intent to treat response rate of 56% (95% CI: 41%-71%). Twelve patients had stable disease for > or = 9 weeks (3 cycles). The median time to progression and overall survival were 6.6 and 9 months, respectively. Grade > or = 3 toxicities were neutropenia 81%, anemia 32%, thrombocytopenia 4%, alopecia 36%, fatigue 9%, mucositis 9%, diarrhea 6%, nausea/vomiting 4%, neurologic 2%, and one anaphylaxis precluding treatment administration. We recorded nine episodes of non-fatal febrile neutropenia in eight patients, two of them with docetaxel at 100 mg/m2. There were no direct treatment-related deaths. CONCLUSIONS TC is active in AGC with a high response rate in a multicentric trial. Despite its hematotoxicity, this regimen is well tolerated and can be recycled as originally planned in 78% of the cases. These results may serve as basis for further developments of docetaxel containing regimens in this disease.
Collapse
Affiliation(s)
- A D Roth
- Department of Surgery, Hôpital Cantonal Universitaire, Geneva, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Sessa C, Wanders J, Roelvink M, Dombernowsky P, Nielsen D, Morant R, Drings P, Wissel P, Hanauske AR. Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 2000; 11:207-10. [PMID: 10761757 DOI: 10.1023/a:1008372404504] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND GI147211, a 10,11-ethylenedioxy substituted analogue of camptothecin (CPT), was brought into clinical development because of its higher water solubility and greater potency as compared to topotecan (TPT). The antitumor activity of GI147211 as second-line therapy in small-cell lung cancer (SCLC) was assessed after stratification of patients in refractory (no response to initial treatment or relapse within three months from last cycle) and chemosensitive (relapse more than three months from last cycle). PATIENTS AND METHODS Sixty-seven patients were entered in the study and sixty-two were evaluable for response, twenty-eight in the refractory and thirty-four in the chemosensitive group. All patients had received 1 line of chemotherapy; radiation had also been given in 29 cases, 6 in the refractory and 23 in the chemosensitive group. GI147211 was administered at 1.2 mg/m2/day as 30-min infusion for five consecutive days every three weeks. RESULTS The overall response rate was 16.6% (11 of 66 patients; 95% confidence interval (95% CI): 8.5%-27.5%), 10.3% (3 of 29 patients; 95% CI: 2.2%-27%) in the refractory and 21.1% (8 of 37 patients; 95% CI: 9.5%-37%) in the chemosensitive group. Only partial responses (PR) were observed with a median duration of PR of 4.8 months (5.7 months in the refractory and 5.2 in the chemosensitive group). Hematological toxicity consisted mainly of neutropenia (grades 3-4 in 25% of cycles) and thrombocytopenia (grades 3-4 in 23% of cycles); non-hematological toxicity was mild to moderate and consisted of nausea (22% of cycles), vomiting (11%), malaise (34%). CONCLUSIONS At the dose and schedule tested GI147211 is an active new agent for second-line treatment of SCLC; the antitumor activity and toxicity profile are comparable to those observed with TPT which remains the leading CPT analogue for salvage treatment. Interest has been renewed in the clinical development of GI147211 by preclinical data with the liposomal formulation showing an increased therapeutic index.
Collapse
Affiliation(s)
- C Sessa
- EORTC Early Clinical Studies Group, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Morant R, Bernhard J, Maibach R, Borner M, Fey MF, Thürlimann B, Jacky E, Trinkler F, Bauer J, Zulian G, Hanselmann S, Hürny C, Hering F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11:183-8. [PMID: 10761753 DOI: 10.1023/a:1008332724977] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND In a phase II trial, 43 patients with hormone-refractory prostate cancer were treated with gemcitabine at a dose of 1,200 mg/m2 over 2 hours (later decreased to 1,000 mg/m2 due to hematological toxicity) on days 1, 8 and 15 of a 28 day cycle. PATIENTS AND METHODS Inclusion criteria were proven tumor progression after hormonal treatment and increased PSA levels, a WHO PS < or = 2, adequate bone marrow reserve, liver and renal function and age < or =, 80 years. Response criteria were based on PSA levels (CR: normalization of PSA, PR: > 50% decrease). Quality of life (QL) was assessed with the EORTC QLQ-C30 on day 1 of each treatment cycle and on day 8 of the first cycle (range of scales 0-100). Physician-rated pain intensity and use of pain medication were assessed at the same timepoints. RESULTS Hematological toxicity of gemcitabine led to a dose-reduction in 48% of all cycles. Three of forty-three patients (RR = 7%) showed a PSA response: one CR and three PR with time to treatment failure of 8.7, 6.6 and > or = 9.3 months. Seven patients (16%) had stable disease (NC) for a median duration of 7.1 months (range 6.1-11.7 months). There was one case with objective regression of lymph node metastases. Patients reported a considerably impaired health status/QL (n = 41, median = 50) and severe fatigue (n = 41, median = 55.6) at baseline, with no change under treatment. Pain (QLQ-C30) was also severe at baseline (N=41, median=50) but was improved at the end of cycles 1 (n = 33, median change = -16.7, P = 0.0002), 2 (n = 19, median change = -33.3, P = 0.0006), 3 (n = 14, median change = -16.7, P = 0.06) and 4 (n = 9, median change = -33.3, P = 0.04). Patient-rated pain and use of analgesics as combined endpoint yielded palliation for at least 8 weeks in 14 patients (32%). Nine of these patients showed at least stable disease (CR/PR or NC by PSA level), five indicated a benefit in spite of progressive disease. CONCLUSIONS Gemcitabine in the dose and schedule indicated above has a significant beneficial impact on pain in patients with hormone-refractory prostatic carcinoma despite its limited activity in terms of PSA response and considerable, especially hematological, toxicity.
Collapse
|